Menu Search
Equities

Carasent ASA

CARA:OSL

Carasent ASA

Actions
Health CareHealth Care Providers
  • Price (NOK)20.00
  • Today's Change0.00 / 0.00%
  • Shares traded131.32k
  • 1 Year change+84.84%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform0
Hold0
Sell0
Strong Sell0

Share price forecast in NOK

The 2 analysts offering 12 month price targets for Carasent ASA have a median target of 26.75, with a high estimate of 27.00 and a low estimate of 26.50. The median estimate represents a 33.75% increase from the last price of 20.00.
High35.0%27.00
Med33.8%26.75
Low32.5%26.50

Earnings history & estimates in NOK

On Oct 24, 2024, Carasent ASA reported 3rd quarter 2024 earnings of 0.06 per share. This result was in line with the expectation of the one analyst following the company and outperformed last year's 3rd quarter results by 0.065.
The next earnings announcement is expected on Feb 13, 2025.
Average growth rate+69.23%
Carasent ASA reported annual 2023 earnings of 0.143 per share on Feb 15, 2024.
Average growth rate+34.25%
More ▼

Revenue history & estimates in NOK

Carasent ASA had 3rd quarter 2024 revenues of 66.31m. This bettered the 65.00m consensus of the 2 analysts covering the company. This was 10.62% above the prior year's 3rd quarter results.
Average growth rate+4.80%
Carasent ASA had revenues for the full year 2023 of 243.98m. This was 24.95% above the prior year's results.
Average growth rate+53.88%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.